Kliničke studije za Debljina u državi Oklahoma
21 studija za Debljina traži sudionike na lokacijama u državi Oklahoma.
Gradovi u državi Oklahoma
Službeni tekst studije (engleski)
A Research Study on How Well Cagrilintide and CagriSema Work in Children and Adolescents With Excess Body Weight
- Children's Physicians OU, Oklahoma City
U tijeku regrutacijaFaza 3
Od 8 do 18 godina · Oba spola · Ažurirano 30. ruj 2026. · NCT07253285Study to Assess the Effect and Safety of ALV-100 on Maintenance of Weight Loss
- Lynn Health Science Institute, Oklahoma City
U tijeku regrutacijaFaza 2
Od 18 do 75 godina · Oba spola · Ažurirano 28. ruj 2026. · NCT07837973AMAZE 9: A Research Study Investigating How Well Zenagamtide Tablets Help People With Excess Body Weight Lose Weight
- Lynn Institute of Norman, Norman
U tijeku regrutacijaFaza 3
Od 18 godina i više · Oba spola · Ažurirano 28. ruj 2026. · NCT07720271A Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040)
- University of Oklahoma Health Sciences Center, Oklahoma City
U tijeku regrutacijaFaza 3
Od 6 do 17 godina · Oba spola · Ažurirano 24. ruj 2026. · NCT06672549Efficacy and Safety of Eloralintide (LY3841136) in Participants With Osteoarthritis Knee Pain and Obesity or Overweight
- Central States Research, Tulsa
U tijeku regrutacijaFaza 3
Od 18 godina i više · Oba spola · Ažurirano 22. ruj 2026. · NCT07353931A Study of Once-daily Oral ASC30 to Evaluate the Efficacy and Safety in Adult Participants With Obesity or Overweight With Type 2 Diabetes
- AURORA-2 Clinical Site, Oklahoma City
U tijeku regrutacijaFaza 3
Od 18 godina i više · Oba spola · Ažurirano 16. ruj 2026. · NCT07743450Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity
- South Oklahoma Heart Research, Oklahoma City
U tijeku regrutacijaFaza 3
Od 18 do 99 godina · Oba spola · Ažurirano 16. ruj 2026. · NCT07037459A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight and Type 2 Diabetes
- Lynn Institute of Norman, Norman
- Lynn Health Science Institute, Oklahoma City
- Essential Medical Research, Tulsa
U tijeku regrutacijaFaza 3
Od 18 godina i više · Oba spola · Ažurirano 14. ruj 2026. · NCT07351058A Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide
- Alliance for Multispecialty Research, LLC, Norman
U tijeku regrutacijaFaza 2
Od 18 do 75 godina · Oba spola · Ažurirano 14. ruj 2026. · NCT06897475A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight Without Type 2 Diabetes
- Delricht Research of Tulsa Clinical Trials, Tulsa
U tijeku regrutacijaFaza 3
Od 18 godina i više · Oba spola · Ažurirano 14. ruj 2026. · NCT07351045A Study of Aleniglipron in Adults With Obesity or Overweight and Type 2 Diabetes Mellitus (ACCOMPLISH-2)
- ACCOMPLISH-2 Research Site, Moore
- ACCOMPLISH-2 Research Site, Tulsa
- ACCOMPLISH-2 Research Site, Yukon
U tijeku regrutacijaFaza 3Zdravi dobrovoljci dobrodošli
Od 18 do 79 godina · Oba spola · Ažurirano 11. ruj 2026. · NCT07654374Efficacy and Safety of Ribupatide Administered Once Weekly in Participants Living With Obesity or Overweight and Diabetes
- Kailera Clinical Site, Chickasha
U tijeku regrutacijaFaza 3
Od 18 godina i više · Oba spola · Ažurirano 3. ruj 2026. · NCT07284901Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-1-EXTENSION)
- Alliance for Multispecialty Research - Norman, Norman
U tijeku regrutacijaFaza 3
Od 18 do 99 godina · Oba spola · Ažurirano 3. ruj 2026. · NCT07684235Efficacy and Safety of Ribupatide in Participants Living With Obesity or Overweight With Weight-Related Comorbidities Who Do Not Have Diabetes
- Kailera Clinical Site, Chickasha
U tijeku regrutacijaFaza 3
Od 18 godina i više · Oba spola · Ažurirano 3. ruj 2026. · NCT07284875Efficacy and Safety of Ribupatide Administered Once Weekly Compared With Semaglutide and Placebo in Participants Living With Obesity Who Do Not Have Diabetes
- Kailera Clinical Site, Norman
U tijeku regrutacijaFaza 3
Od 18 godina i više · Oba spola · Ažurirano 1. ruj 2026. · NCT07284979Efficacy, Safety and Tolerability of Switching From Glucagon-like Peptide-1 Receptor Agonists (GLP-1RA) to Maridebart Cafraglutide in Adults With Obesity or Overweight (MARITIME-SWITCH)
- Epic Medical Research - Oklahoma, Chickasha
- Lynn Health Science Institute, Oklahoma City
U tijeku regrutacijaFaza 3
Od 18 do 99 godina · Oba spola · Ažurirano 27. kol 2026. · NCT07575399A Study to Evaluate Effect of AZD6234 in Adult Participants With Obesity or Overweight With Weight-related Comorbidity Without Type 2 Diabetes Mellitus
- Research Site, Tulsa
U tijeku regrutacijaFaza 3
Od 18 godina i više · Oba spola · Ažurirano 25. kol 2026. · NCT07784725Efficacy and Safety of Aleniglipron in Participants With Obesity or Overweight With a Weight-Related Comorbidity (ACCOMPLISH-1)
- ACCOMPLISH-1 Research Site, Moore
U tijeku regrutacijaFaza 3
Od 18 do 79 godina · Oba spola · Ažurirano 10. kol 2026. · NCT07654361A Study to See How Safe and Effective Alirocumab is When Given Weekly to Adult Participants Who Have Hypercholesterolemia
- AMR Norman, Norman
- Lynn Health Science Institute, Oklahoma City
U tijeku regrutacijaFaza 2
Od 18 do 80 godina · Oba spola · Ažurirano 22. srp 2026. · NCT07477704Intensive Glycemic Targets in Overweight and Obese Women With Gestational Diabetes
- University of Oklahoma, Norman
U tijeku regrutacija
Od 18 do 45 godina · Žene · Ažurirano 24. lip 2026. · NCT05124808Uterine Preservation Via Lifestyle Transformation
- University of Oklahoma, Oklahoma City
U tijeku regrutacijaFaza 2
Od 18 godina i više · Žene · Ažurirano 20. sij 2026. · NCT05903131Iz ClinicalTrials.gov, podaci preuzeti 5. lis 2026.. Svaka studija ima svoje uvjete prihoda; tim studije odlučuje tko se može priključiti.